Adipose tissue and muscle attenuation as novel biomarkers predicting mortality in patients with extremity sarcomas
- 387 Downloads
To assess CT-attenuation of abdominal adipose tissue and psoas muscle as predictors of mortality in patients with sarcomas of the extremities.
Our study was IRB approved and HIPAA compliant. The study group comprised 135 patients with history of extremity sarcoma (mean age: 53 ± 17 years) who underwent whole body PET/CT. Abdominal subcutaneous adipose tissue (SAT), visceral adipose tissue (VAT), and psoas muscle attenuation (HU) was assessed on non-contrast, attenuation-correction CT. Clinical information including survival, tumour stage, sarcoma type, therapy and pre-existing comorbidities were recorded. Cox proportional hazard models were used to determine longitudinal associations between adipose tissue and muscle attenuation and mortality.
There were 47 deaths over a mean follow-up period of 20 ± 17 months. Higher SAT and lower psoas attenuation were associated with increased mortality (p = 0.03 and p = 0.005, respectively), which remained significant after adjustment for age, BMI, sex, tumor stage, therapy, and comorbidities (p = 0.002 and p = 0.02, respectively). VAT attenuation was not associated with mortality.
Attenuation of SAT and psoas muscle, assessed on non-contrast CT, are predictors of mortality in patients with extremity sarcomas, independent of other established prognostic factors, suggesting that adipose tissue and muscle attenuation could serve as novel biomarkers for mortality in patients with sarcomas.
• CT-attenuation of adipose tissue and muscle predict mortality in sarcoma patients
• CT-attenuation predicts mortality independent of established prognostic factors
• Patients with sarcomas often undergo CT for staging or surveillance
• Adipose tissue and muscle attenuation could serve as biomarkers for mortality
KeywordsComputed tomography (CT) Adipose tissue attenuation Muscle attenuation Hounsfield Units Sarcoma
The scientific guarantor of this publication is Miriam A. Bredella. The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article. The authors state that this work has not received any funding. Elkan F. Halpern, Director of Statistics of the Department of Radiology at MGH and co-author on the study kindly provided statistical advice for this manuscript. Institutional Review Board approval was obtained. Written informed consent was waived by the Institutional Review Board. Methodology: retrospective, observational, performed at one institution.
Compliance with ethical standards
Conflict of interest
The authors have no conflict of interest to declare.
- 2.Morrison BA (2003) Soft tissue sarcomas of the extremities. Proc (Baylor Univ Med Cent) 16:285–290Google Scholar
- 5.Nieman KM, Romero IL, Van Houten B, Lengyel E (1831) Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta 2013:1533–1541Google Scholar
- 18.Tamandl D, Paireder M, Asari R et al () Markers of sarcopenia quantified by computed tomography predict adverse long-term outcome in patients with resected oesophageal or gastro-oesophageal junction cancer. Eur RadiolGoogle Scholar
- 34.Goodpaster BH, Kelley DE, Thaete FL et al (2000) Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content. J Appl Physiol (1985) 89:104–110Google Scholar
- 37.Goodpaster BH, Carlson CL, Visser M et al (2001) Attenuation of skeletal muscle and strength in the elderly: the health ABC study. J Appl Physiol (1985) 90:2157–2165Google Scholar